Polaryx Therapeutics, Inc. (PLYX) – What Are Investment Firms Thinking About This Stock?

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) have been assigned an average rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.67.

Several equities analysts have recently weighed in on the stock. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th. HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Raymond James Financial initiated coverage on Polaryx Therapeutics in a research report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 target price for the company.

Polaryx Therapeutics Stock Down 5.9%

Shares of NASDAQ:PLYX opened at $1.75 on Tuesday. The company has a market cap of $87.24 million and a PE ratio of -21.88. The company’s 50-day moving average price is $2.01 and its 200 day moving average price is $3.14. Polaryx Therapeutics has a fifty-two week low of $1.75 and a fifty-two week high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. As a group, equities analysts anticipate that Polaryx Therapeutics will post -0.22 EPS for the current year.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.